Editas Medicine
Editas Medicine raises $118M Follow-on Offering at $1.8B valuation
Editas Medicine: Follow-on Offering Funding Round
Editas Medicine has successfully raised $118M in Follow-on Offering funding, reaching a valuation of $1.8B.
Company Overview
Genome editing medicines
Funding Details
The Follow-on Offering round was led by Polaris Partners, with participation from Flagship Pioneering, Third Rock Ventures, Google Ventures.
Company Information
- Headquarters: 11 Hurley Street, Cambridge, MA 02141
- Founded: 2013
- Employees: 300+
- Category: Biotech
Investment
Editas Medicine plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Polaris Partners: Verified investor in Follow-on Offering
- Flagship Pioneering: Verified investor in Follow-on Offering
- Third Rock Ventures: Verified investor in Follow-on Offering
- Google Ventures: Verified investor in Follow-on Offering
Company Info
Investors (4)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free